As the world scrambles to repurpose approved treatments and develop new ones to tackle the deadly coronavirus, Indian firms are moving quietly alongside in sync, hoping to accelerate development activities or scale up plans for such potential therapies. Domestic firms are also keeping close watch on developments around an encouraging French study on the potential of hydroxychloroquine and azithromycin as a treatment for COVID-19.
India COVID-19 Update: Antivirals, Eyes On HCQ-Azithromycin Data
Cipla Among Firms Prepping Favipiravir, Remdesivir, Baloxavir Generics
Development work for antivirals such as favipiravir and remdesivir seen as potential treatments for coronavirus is underway in India, with the former’s off-patent status making it more attractive. All eyes are also on data from a French study which highlights the potential of hydroxychloroquine and azithromycin as a COVID-19 treatment.

More from R&D
With new Phase II data, Edgewise asserted that EDG-7500, a sarcomere modulator, could offer better efficacy and safety than cardiac myosin inhibitors in hypertrophic cardiomyopathy.
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
More from Scrip
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
After a more than three-year hiatus, China's Hengrui has signalled its return to multiregional Phase III trials as it looks to globalize its innovative pipeline. Meanwhile, a number of other Chinese players have announced plans to kick off Phase III trials this year and beyond.
The latest in a long line of restructuring measures will see Sumitomo Pharma making a stepped sale of its pharma operations in Asia to major Japanese trading house Marubeni.